Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $36,300.00 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $25.00, for a total transaction of $36,300.00. Following the completion of the transaction, the insider owned 117,227 shares of the company’s stock, valued at $2,930,675. This represents a 1.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total value of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total value of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total transaction of $89,942.86.

Nurix Therapeutics Trading Up 5.4%

Shares of NRIX stock traded up $1.28 during trading hours on Thursday, hitting $24.95. The company’s stock had a trading volume of 3,753,438 shares, compared to its average volume of 1,512,604. The business has a fifty day moving average of $25.14 and a 200-day moving average of $21.06. Nurix Therapeutics, Inc. has a twelve month low of $9.71 and a twelve month high of $28.23. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of 10.80 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 62.20% and a net margin of 42.01%. The firm had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. On average, equities analysts expect that Nurix Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Key Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst maintained a “Strong Buy” rating, citing promising earlier-stage data, potential accelerated approval and multiple development opportunities. Bexobrutideg clinical analysis
• Positive Sentiment: Analyst sentiment remains broadly bullish. Baird raised its price target to $36 and maintained an “Outperform” rating, while Needham reiterated “Buy” with a $34 target. The consensus target is approximately $34.64, above recent trading levels. Nurix analyst ratings
• Neutral Sentiment: Nurix’s quarterly results significantly exceeded estimates, with earnings of $4.73 per share versus a projected loss of $0.60 and revenue of $673.06 million versus a $24.35 million consensus estimate. However, the earnings reaction was tempered by higher operating expenses as the company continues investing in its pipeline. Nurix quarterly earnings
• Negative Sentiment: Truist reduced its price target for Nurix while retaining a “Buy” rating, signaling more cautious near-term expectations despite confidence in the company’s longer-term prospects. Truist price target update
• Negative Sentiment: Director Julia Gregory sold 22,583 shares for about $528,000, reducing her direct ownership by 67.75%. Separately, insider Gwenn Hansen sold 1,452 shares for $36,300 under a pre-arranged Rule 10b5-1 plan. While planned sales may reflect diversification or personal financial needs, the transactions can weigh on investor sentiment. Nurix insider sale filing

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds have recently made changes to their positions in NRIX. General Atlantic L.P. purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at $92,899,000. Trails Edge Capital Partners LP purchased a new position in Nurix Therapeutics during the second quarter worth about $38,166,318. Bank of New York Mellon Corp purchased a new position in Nurix Therapeutics during the second quarter worth about $6,614,000. Man Group plc acquired a new stake in Nurix Therapeutics in the 2nd quarter worth about $2,076,000. Finally, Baker BROS. Advisors LP boosted its stake in Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after buying an additional 776,431 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on NRIX shares. Stifel Nicolaus set a $41.00 price objective on Nurix Therapeutics in a research note on Tuesday. UBS Group upped their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Robert W. Baird raised their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.64.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.